Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDGN201 TARGTEPO in Anemia of ESRD
NCT02468414Phase 2Terminated
- Sponsor
- Avalo Therapeutics
- Start
- Jun 2015
- Primary completion
- May 2016
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of MDGN201 in anemia, sponsored by Avalo Therapeutics. Started Jun 2015; status: terminated.
02
Drugs
MDGN201
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02468414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02468414.